
https://www.science.org/content/blog-post/predicting-what-group-put-next
# Predicting What R Group to Put On Next (March 2014)

## 1. SUMMARY

This 2014 commentary discusses a newly published *J. Med. Chem.* paper describing Matsy, software designed to recommend which R groups medicinal chemists should synthesize next during lead optimization. The approach uses matched-molecular-pair (MMP) analysis to identify preferred activity orderings of substituent series (e.g., for halogens, finding that Br > Cl > F > H was the most common potency trend, likely driven by lipophilicity effects). The commentary contextualizes this by referencing a key 2008 Abbott study of 84,000 compounds across 30 targets that suggested most R-group replacements show near-zero average effect on potency, implying that such predictions are most useful when applied within the same target or assay rather than across diverse systems. The author frames Matsy as formalizing how medicinal chemists already work—observing trends and using chemical intuition—while walking a fine line between recommending obvious changes and suggesting synthetically impractical structures.

## 2. HISTORY

The 2014 discussion sits within a broader trajectory of computational tools for structure–activity relationship (SAR) guidance and lead optimization. Subsequent developments reflect both adoption and evolution away from the specific approach:

- **Matched-molecular-pair (MMP) analysis tools continued to mature** in pharma workflows for retrospective analysis of large datasets, but the specific "Matsy" software did not become a dominant recommendation engine.
- **QIAN et al. (2014) on "SAR transfer" contributed to the ongoing methodological debate.** Such approaches faced the same core challenge the Abbott (2008) data highlighted: global trends do not reliably predict within-series behavior.
- **"Magic methyl" effects remained important but uncommon.** Real-world drug discovery confirmed that individual methyl additions can yield large potency gains, but systematic studies kept showing these are outliers relative to the near-neutral average impact.
- **The field moved to hybrid approaches:** Physics-based Free Energy Perturbation (FEP) gained traction for more rigorous binding-affinity prediction, while machine learning and deep learning for molecular property prediction (fingerprint, graph neural networks) exceeded MMP recommendations in both adoption and accuracy. MMP is now more frequently used for filtering, sanity-checking, and rule mining than for primary recommendations.

In-house company tests likely followed, and the overall pattern suggests that while the "obvious vs impractical" dilemma persisted, the most successful computational tools were those that integrated multiple methods (ML, physics, expert rules) and tailored predictions to specific protein families or assay contexts.

## 3. PREDICTIONS

- **Prediction: Matsy would find its niche where recommendation boundaries lie between "obvious" and "impractical."**  
  - Outcome: The software and its algorithm remained a methodological contribution rather than a widely adopted commercial or open-source tool. Broader computational drug discovery moved toward fingerprint-based similarity, graph neural networks, and physics-based methods. Matsy-style formalisms did not displace chemical intuition.

- **Prediction: Companies trying Matsy in-house would determine whether it provided actionable guidance.**  
  - Outcome: Within pharma, recommendation tools evolved into integrated suites (e.g., combining ML scoring, retrosynthesis planning, and ADMET predictions). Standalone R-group recommendation engines of the Matsy type became less common as workflow integration grew more important.

- **Implicit prediction: The findings would encourage analysis within the same target or assay rather than global averages.**  
  - Outcome: Subsequent methods and best practices increasingly emphasized context-sensitivity and target-family modeling, aligning with the article's intuition, albeit through different technical routes (e.g., multitask models and transfer learning on protein family datasets).

## 4. INTEREST

Rating: **4/10**

This is a competent but niche commentary on an incremental methodological paper; it does not signal a paradigm shift and was soon overtaken by broader ML advances in molecular property prediction.


----
_model_params = {'model': 'nex-agi/deepseek-v3.1-nex-n1:free', 'input': '20140317-predicting-what-group-put-next.txt', 'reasoning': {'effort': 'high'}, 'text': {'verbosity': 'medium'}, 'prompt-template': 'prompt-template-2'}_